唑来膦酸与认知障碍老年人的骨骼健康
本研究为随机双盲安慰剂对照试验的事后二次分析,纳入179名≥65岁居住于辅助生活机构或养老院的女性,其中43名存在轻至重度认知障碍。结果显示,认知障碍者接受单剂唑来膦酸12个月后全髋和股骨颈骨密度分别较安慰剂组高4.3%(p=.005)和5.3%(p<.001),骨转换标志物6个月时显著下降,且改善程度与无认知障碍者相似。
要点
- 认知障碍老年女性使用唑来膦酸后全髋骨密度较安慰剂组高4.3%(p=.005)。
- 股骨颈骨密度较安慰剂组高5.3%(p<.001),改善程度与无认知障碍者相似。
- 6个月时骨转换标志物显著下降,提示治疗可改善该人群骨骼健康。
核心结论
- 唑来膦酸可改善认知障碍的衰弱老年女性的骨骼健康,效果与无认知障碍者相似。
研究设计与样本
- 随机双盲安慰剂对照试验的事后二次分析,纳入179名≥65岁居住于辅助生活机构或养老院的女性,其中43名有轻至重度认知障碍。
主要发现
- 认知障碍者接受唑来膦酸12个月后全髋骨密度较安慰剂组高4.3%(p=.005)。
- 股骨颈骨密度较安慰剂组高5.3%(p<.001)。
- 认知障碍者接受活性治疗6个月时骨转换标志物较安慰剂组显著下降。
- 唑来膦酸对骨骼健康指标的改善与无认知障碍者相似。
临床怎么用
- 对于认知障碍的衰弱老年女性,可考虑使用唑来膦酸以改善骨密度和骨转换标志物。
局限性
- 本研究为事后二次分析,样本量有限,且需进一步研究评估该人群的骨折减少获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Fracture prevention in cognitively impaired individuals is lacking. This work highlights the benefits of zoledronic acid on bone health in cognitively impaired older adults. Demonstrating benefits of therapy may increase treatment uptake and reduce fracture risk in this group. INTRODUCTION: Osteoporosis has detrimental consequences for frail older adults. The effects on those with both osteoporosis and cognitive impairment are compounded due to increased risk of falls and changes in mobility, both of which can lead to fracture. However, there are limited data on treatment benefits for osteoporotic individuals with cognitive impairment. METHODS: This post hoc, secondary analysis of data from a randomized, double-blind, placebo-controlled clinical trial of single-dose zoledronic acid included 179 women age ≥ 65 years residing in assisted living facilities or nursing homes, 43 of whom had mild to severe cognitive impairment. We assessed bone mineral density (BMD) of the total hip, femoral neck, and lumbar spine by dual-energy x-ray absorptiometry and serum bone turnover markers (C-terminal telopeptide of type I collagen and procollagen type I N propeptide) at 6 and 12 months. RESULTS: In participants with cognitive impairment, those who received zoledronic acid had 4.3% greater BMD at the total hip (p=.005) and 5.3% greater BMD at the femoral neck (p<.001) after 12 months compared to those in the placebo group. Bone turnover markers demonstrated significant decreases at 6 months in those with cognitive impairment who received active treatment compared to the placebo group. Improvements in bone health measures with zoledronic acid were similar to those seen in participants without cognitive impairment. CONCLUSION: Zoledronic acid improves bone health in frail older women with cognitive impairment similar to those without impairment. Further studies are warranted to assess the benefit for fracture reduction in this undertreated population.
引用
- Churilla BM, Perera S, Greenspan SL, et al. Zoledronic acid and bone health in older adults with cognitive impairment. Osteoporos Int. 2021. PMID: 34341833. doi:10.1007/s00198-021-06063-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。